CD1d–invariant Natural Killer T cell T-cell receptor complex (CD1d–iNKT TCR complex)

The CD1d–invariant Natural Killer T (iNKT) cell T-cell receptor (TCR) complex is a pivotal immunological assembly that facilitates the recognition of lipid antigens. CD1d is a non-polymorphic MHC class I-like molecule that presents endogenous and exogenous glycolipids to a specialized subset of T cells known as iNKT cells [UniProt: P15813]. These cells express a semi-invariant TCR, typically composed of a Vα24-Jα18 chain in humans, which recognizes the CD1d-lipid complex with high specificity [PMID: 17299405]. Upon activation, the complex triggers a rapid and robust release of cytokines, including IFN-γ and IL-4, allowing iNKT cells to orchestrate both innate and adaptive immune responses [PMID: 24018268]. This interaction is a major therapeutic target in cancer immunotherapy and vaccine development, as iNKT activation can stimulate potent anti-tumor activity [PMID: 30108264]. Synthetic agonists like Alpha-galactosylceramide (α-GalCer) and its derivatives, such as ABX196, are designed to bind CD1d and potently activate the iNKT TCR to modulate immune outcomes [ClinicalTrials.gov: NCT04387526]. However, therapeutic application is challenged by the potential for iNKT cell anergy and the risk of systemic cytokine release syndrome [PMID: 21904387].

Other names

CD1d-iNKT TCRCD1d-Vα24-Jα18 TCR complexCD1d-lipid-TCR complexCD1d-invariant NKT TCRCD1d-TRAV10-TRAJ18 complex

Agonist binding to the iNKT TCR when presented by CD1d, leading to rapid activation of iNKT cells and subsequent release of Th1 and Th2 cytokines.